Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109,153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study.
Yang Y, Sun J, Wang Z, Fang J, Yu Q, Han B, Cang S, Chen G, Mei X, Yang Z, Ma R, Bi M, Ren X, Zhou J, Li B, Song Y, Feng J, Li J, He Z, Zhou R, Li W, Lu Y, Zhou H, Wang S, Sun L, Puig O, Mancao C, Peng B, Fang W, Xu W, Zhang L. Yang Y, et al. Among authors: yang z. J Thorac Oncol. 2021 Dec;16(12):2109-2120. doi: 10.1016/j.jtho.2021.07.015. Epub 2021 Aug 3. J Thorac Oncol. 2021. PMID: 34358724 Free article.
Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC.
Wu X, Liang W, Hou X, Lin Z, Zhao H, Huang Y, Fang W, Zhao Y, Wu J, Yang Y, Xue C, Hu Z, Zhang J, Zhang J, Ma Y, Zhou T, Qin T, Zhang L. Wu X, et al. Among authors: yang y. Onco Targets Ther. 2013 Oct 21;6:1481-91. doi: 10.2147/OTT.S51887. eCollection 2013. Onco Targets Ther. 2013. PMID: 24204163 Free PMC article.
Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
Liang W, Wu X, Fang W, Zhao Y, Yang Y, Hu Z, Xue C, Zhang J, Zhang J, Ma Y, Zhou T, Yan Y, Hou X, Qin T, Dinglin X, Tian Y, Huang P, Huang Y, Zhao H, Zhang L. Liang W, et al. Among authors: yang y. PLoS One. 2014 Feb 12;9(2):e85245. doi: 10.1371/journal.pone.0085245. eCollection 2014. PLoS One. 2014. PMID: 24533047 Free PMC article.
Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials.
Hong S, Fang W, Liang W, Yan Y, Zhou T, Qin T, Wu X, Ma Y, Zhao Y, Yang Y, Hu Z, Xue C, Hou X, Chen Y, Huang Y, Zhao H, Zhang L. Hong S, et al. Among authors: yang y. Onco Targets Ther. 2014 Oct 7;7:1851-67. doi: 10.2147/OTT.S68386. eCollection 2014. Onco Targets Ther. 2014. Retraction in: Onco Targets Ther. 2016 Oct 20;9:6377. doi: 10.2147/OTT.S124095 PMID: 25336977 Free PMC article. Retracted.
EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy.
Fang W, Zhang J, Hong S, Zhan J, Chen N, Qin T, Tang Y, Zhang Y, Kang S, Zhou T, Wu X, Liang W, Hu Z, Ma Y, Zhao Y, Tian Y, Yang Y, Xue C, Yan Y, Hou X, Huang P, Huang Y, Zhao H, Zhang L. Fang W, et al. Among authors: yang y. Oncotarget. 2014 Dec 15;5(23):12189-202. doi: 10.18632/oncotarget.2608. Oncotarget. 2014. PMID: 25361008 Free PMC article.
109,153 results
You have reached the last available page of results. Please see the User Guide for more information.